Key result
Bioprosthetic tricuspid valves show no benefit over mechanical valves for long-term mortality or reoperation.
Why the study?
The ideal valve substitute for tricuspid valve replacement in patients with severe isolated tricuspid regurgitation remains unclear.
Does bioprosthetic tricuspid valve replacement improve outcomes compared to mechanical tricuspid valve replacement in patients with severe isolated tricuspid regurgitation?
Cohort (n=76)
No
Does bioprosthetic tricuspid valve replacement improve outcomes compared to mechanical tricuspid valve replacement in patients with severe isolated tricuspid regurgitation?
In patients with severe isolated tricuspid regurgitation undergoing first-time replacement, there is no significant difference in survival or reoperation rates between bioprosthetic and mechanical valves.
Answers are grounded in this paper and cite their sources.
No difference in outcomes supports individualized prosthesis selection; leaves open need for randomized trials in isolated tricuspid replacement.
OBJECTIVE: The ideal alternative for tricuspid valve replacement (TVR) in patients with severe isolated tricuspid regurgitation remains unclear. The aim of the present study was to retrospectively investigate the outcomes of using bioprosthetic and mechanical valves at the tricuspid position. METHODS: A total of 98 consecutive patients without left-side cardiac disease or history of heart surgery who underwent first-time TVR between January 2010 and March 2017 at the West China Hospital, China were included in the study. Patient data, including all-cause death and need for tricuspid valve reoperation as the main end points, were retrospectively evaluated. RESULTS: A total of 76 patients were enrolled into the study. The mean follow-up period was 43.3±21.9 (10-87) months. The mean age of the patients was 45.7±13.4 years. The study comprised 32.9% of male patients. During the follow-up period, 4, 3, 12, and 3 cases of death, reoperation, prosthesis dysfunctions, and prosthesis-related thrombosis were noted, respectively. Biological and mechanical valves were used in 56.6% and 43.4% of the patients, respectively. However, there was no significant difference between mechanical and biological valves with respect to echocardiographic date and survival, reoperation, prosthetic valve dysfunction, and thromboembolism rate. CONCLUSION: TVR is not a very high-risk procedure in patients with isolated tricuspid regurgitation, and the decision for prosthesis implantation in TVR should be made on an individual basis according to suitable clinical judgment.
No takes yet. Share an insight, caveat, or question.
Weitao Liang (2019) conducted a cohort in Severe isolated tricuspid regurgitation (n=76). Bioprosthetic valve vs. Mechanical valve was evaluated on All-cause mortality (p=0.719). Bioprosthetic and mechanical valves showed no significant difference in long-term mortality or need for reoperation after first-time tricuspid valve replacement.
Synapse has enriched 10 related papers. Consider them for comparative context: